The funding package includes a £2.5m loan along with ancillary facilities for four years through to December 2015.
SEP is focused on marketing products related to urology and uro-oncology to treat various diseases including prostate cancer, bladder cancer and overactive bladder.
The company’s products are marketed directly in France, Germany, Italy and in the UK.